Literature DB >> 12797957

Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.

Jon T Willie1, Richard M Chemelli, Christopher M Sinton, Shigeru Tokita, S Clay Williams, Yaz Y Kisanuki, Jacob N Marcus, Charlotte Lee, Joel K Elmquist, Kristi A Kohlmeier, Christopher S Leonard, James A Richardson, Robert E Hammer, Masashi Yanagisawa.   

Abstract

Narcolepsy-cataplexy, a neurological disorder associated with the absence of hypothalamic orexin (hypocretin) neuropeptides, consists of two underlying problems: inability to maintain wakefulness and intrusion of rapid eye movement (REM) sleep into wakefulness. Here we document, using behavioral, electrophysiological, and pharmacological criteria, two distinct classes of behavioral arrests exhibited by mice deficient in orexin-mediated signaling. Both OX2R(-/-) and orexin(-/-) mice are similarly affected with behaviorally abnormal attacks of non-REM sleep ("sleep attacks") and show similar degrees of disrupted wakefulness. In contrast, OX2R(-/-) mice are only mildly affected with cataplexy-like attacks of REM sleep, whereas orexin(-/-) mice are severely affected. Absence of OX2Rs eliminates orexin-evoked excitation of histaminergic neurons in the hypothalamus, which gate non-REM sleep onset. While normal regulation of wake/non-REM sleep transitions depends critically upon OX2R activation, the profound dysregulation of REM sleep control unique to the narcolepsy-cataplexy syndrome emerges from loss of signaling through both OX2R-dependent and OX2R-independent pathways.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797957     DOI: 10.1016/s0896-6273(03)00330-1

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  201 in total

1.  Differential orexin/hypocretin expression in addiction-prone and -resistant rats selectively bred for high (HiS) and low (LoS) saccharin intake.

Authors:  Nathan A Holtz; Natalie E Zlebnik; Marilyn E Carroll
Journal:  Neurosci Lett       Date:  2012-06-02       Impact factor: 3.046

2.  Neuropharmacology of Sleep and Wakefulness.

Authors:  Christopher J Watson; Helen A Baghdoyan; Ralph Lydic
Journal:  Sleep Med Clin       Date:  2010-12

Review 3.  Sleep and obesity: a focus on animal models.

Authors:  Vijayakumar Mavanji; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Neurosci Biobehav Rev       Date:  2012-01-16       Impact factor: 8.989

4.  The injection of hypocretin-1 into the nucleus pontis oralis induces either active sleep or wakefulness depending on the behavioral state when it is administered.

Authors:  Mingchu Xi; Michael H Chase
Journal:  Sleep       Date:  2010-09       Impact factor: 5.849

Review 5.  Energy expenditure: role of orexin.

Authors:  Jennifer A Teske; Vijayakumar Mavanji
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

6.  Influence of inhibitory serotonergic inputs to orexin/hypocretin neurons on the diurnal rhythm of sleep and wakefulness.

Authors:  Sawako Tabuchi; Tomomi Tsunematsu; Thomas S Kilduff; Shouta Sugio; Ming Xu; Kenji F Tanaka; Satoru Takahashi; Makoto Tominaga; Akihiro Yamanaka
Journal:  Sleep       Date:  2013-09-01       Impact factor: 5.849

7.  Connexin 43-Mediated Astroglial Metabolic Networks Contribute to the Regulation of the Sleep-Wake Cycle.

Authors:  Jerome Clasadonte; Eliana Scemes; Zhongya Wang; Detlev Boison; Philip G Haydon
Journal:  Neuron       Date:  2017-08-31       Impact factor: 17.173

8.  Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.

Authors:  Seiji Nishino; Eiko Sakurai; Sona Nevsimalova; Yasushi Yoshida; Takehiko Watanabe; Kazuhiko Yanai; Emmanuel Mignot
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

9.  Role of orexin/hypocretin in conditioned sucrose-seeking in rats.

Authors:  Angie M Cason; Gary Aston-Jones
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

10.  Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.

Authors:  Jie Yin; Kerim Babaoglu; Chad A Brautigam; Lindsay Clark; Zhenhua Shao; Thomas H Scheuermann; Charles M Harrell; Anthony L Gotter; Anthony J Roecker; Christopher J Winrow; John J Renger; Paul J Coleman; Daniel M Rosenbaum
Journal:  Nat Struct Mol Biol       Date:  2016-03-07       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.